Kymera Therapeutics, Inc.

Biotechnology • Healthcare • Watertown, MA, United States • KYMR (NGM)

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

857 285 5300 500 North Beacon Street, Watertown, MA 02472, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Yahoo Finance

Yahoo Finance • Jan 7

Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - Investing News Network

Investing News Network • Jan 6

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside - DirectorsTalk Interviews

DirectorsTalk Interviews • Jan 6

Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus

GuruFocus • Jan 6

Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. - Barron's

Barron's • Dec 8

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Kymera Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Kymera Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Kymera Therapeutics, Inc. have?

Kymera Therapeutics, Inc. has approximately 225 employees.

What industry is Kymera Therapeutics, Inc. in?

Kymera Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Kymera Therapeutics, Inc. a publicly traded company?

Yes, Kymera Therapeutics, Inc. is publicly traded under the ticker symbol KYMR on the NGM. The company has a market capitalization of approximately $6.51 billion.

Where is Kymera Therapeutics, Inc. headquartered?

Kymera Therapeutics, Inc. is headquartered in Watertown, MA, United States at 500 North Beacon Street, Watertown, MA 02472, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.